Novos, a NYC-based longevity supplements brand, raised $3.15m in pre-seed financing.
The round was led by Resolute Ventures, with participation from Arkitekt Ventures, Longevitytech.fund, Awesome People Ventures and 20 institutional investors and noteworthy entrepreneurs.
The company intends to use the funds to advance clinical research and propel the development of a longevity-focused platform.
Led by Chris Mirabile, founder and CEO, and Kris Verburgh, MD, co-founder and Chief Scientific Officer, Novos is developing science-based products that slow down the aging process. The company’s strategy is to utilize a scientific approach to help consumers navigate the complex market of health and wellness supplements in order to extend lifespan and healthspan by combating cellular aging.